| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| β-内酰胺类抗菌药(元) | 458,520,877.90 | 975,915,065.89 | 499,940,035.99 | 779,273,636.57 | 367,382,633.79 |
| 抗胆碱和合成解痉药(元) | 79,509,325.20 | 159,677,114.41 | 66,222,071.52 | 164,679,191.62 | 62,326,942.71 |
| 喹喏酮类原料药及中间体(元) | 59,343,198.81 | - | 56,078,742.73 | - | 51,932,582.71 |
| 皮肤用抗真菌药(元) | 36,160,798.27 | 77,032,691.41 | 27,953,344.14 | 72,609,682.34 | 27,433,671.34 |
| 喹诺酮类抗菌药(元) | - | 97,063,031.59 | - | 104,753,538.12 | - |
| 其他产品(元) | 11,576,419.59 | 40,902,655.80 | 20,993,073.72 | 52,964,706.23 | 23,715,744.04 |
| 营业成本(元) | |||||
| β-内酰胺类抗菌药(元) | 363,463,390.44 | 773,093,794.66 | - | 686,170,001.30 | - |
| 抗胆碱和合成解痉药(元) | 36,052,798.31 | 75,454,795.65 | - | 83,830,658.40 | - |
| 喹喏酮类原料药及中间体(元) | 53,962,396.14 | - | - | - | - |
| 皮肤用抗真菌药(元) | 19,187,488.99 | 41,421,249.74 | - | 36,598,782.96 | - |
| 喹诺酮类抗菌药(元) | - | 87,661,229.09 | - | 83,886,362.56 | - |
| 其他产品(元) | 7,880,176.68 | 17,189,014.76 | - | 19,672,916.37 | - |
| 毛利(元) | |||||
| β-内酰胺类抗菌药(元) | 95,057,487.46 | 202,821,271.23 | - | 93,103,635.27 | - |
| 抗胆碱和合成解痉药(元) | 43,456,526.89 | 84,222,318.76 | - | 80,848,533.22 | - |
| 喹喏酮类原料药及中间体(元) | 5,380,802.67 | - | - | - | - |
| 皮肤用抗真菌药(元) | 16,973,309.28 | 35,611,441.67 | - | 36,010,899.38 | - |
| 喹诺酮类抗菌药(元) | - | 9,401,802.50 | - | 20,867,175.56 | - |
| 其他产品(元) | 3,696,242.91 | 23,713,641.04 | - | 33,291,789.86 | - |
| 毛利率(%) | |||||
| β-内酰胺类抗菌药(%) | 20.73 | 20.78 | - | 11.95 | - |
| 抗胆碱和合成解痉药(%) | 54.66 | 52.75 | - | 49.09 | - |
| 喹喏酮类原料药及中间体(%) | 9.07 | - | - | - | - |
| 皮肤用抗真菌药(%) | 46.94 | 46.23 | - | 49.60 | - |
| 喹诺酮类抗菌药(%) | - | 9.69 | - | 19.92 | - |
| 其他产品(%) | 31.93 | 57.98 | - | 62.86 | - |
| 收入构成(%) | |||||
| β-内酰胺类抗菌药(%) | 71.08 | 72.26 | 74.49 | 66.36 | 68.95 |
| 抗胆碱和合成解痉药(%) | 12.32 | 11.82 | 9.87 | 14.02 | 11.70 |
| 喹喏酮类原料药及中间体(%) | 9.20 | - | 8.36 | - | 9.75 |
| 皮肤用抗真菌药(%) | 5.61 | 5.70 | 4.16 | 6.18 | 5.15 |
| 喹诺酮类抗菌药(%) | - | 7.19 | - | 8.92 | - |
| 其他产品(%) | 1.79 | 3.03 | 3.13 | 4.51 | 4.45 |
| 毛利构成(%) | |||||
| β-内酰胺类抗菌药(%) | 57.76 | 57.01 | - | 35.25 | - |
| 抗胆碱和合成解痉药(%) | 26.41 | 23.67 | - | 30.61 | - |
| 喹喏酮类原料药及中间体(%) | 3.27 | - | - | - | - |
| 皮肤用抗真菌药(%) | 10.31 | 10.01 | - | 13.63 | - |
| 喹诺酮类抗菌药(%) | - | 2.64 | - | 7.90 | - |
| 其他产品(%) | 2.25 | 6.67 | - | 12.60 | - |